The Evolution, Landscape, and Clinical Tradeoffs of In Vivo CAR-T Therapy
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized hematological oncology, yet conventional ex vivo manufacturing imposes severe clinical and economic burdens. In vivo CAR-T therapy—programming endogenous T cells via systemic vector delivery—has emerged to overcome these limitations. This communication a...